Has Coronavirus Put These Four Pot Stocks on Sale?

As the Coronavirus drives pot stocks further downward, which stocks are on their way out, and which are seemingly undervalued? Find out in this article.

Anyone that’s had their finger on the pulse when it comes to cannabis companies has known that many of the companies we see today may not be around in the next five years. Continuing federal illegality, difficulty in accessing financial institutions and the newness of the industry all coalesce to make the global cannabis industry pretty rocky territory for those within it.

During 2018, capital was flowing into the sector like water from a firehose, with investors desperate to get their hands on a slice of the pie. Unfortunately for cannabis companies, however, the hype quickly wore off, and so too did the flow of capital into the sector. This created the capital crunch of 2019, where we saw many of the major players within the space struggle to make ends meet.

Immediately it became very clear that those without cash, and near-term profitability, wouldn’t stay afloat.

As a result, major players like MedMen began effectively taking a slow walk to their grave, and even giants like Tilray, whose valuation was at an astronomical $7.5…